

IN THE SPECIFICATION:

Please replace the title of the application with the following rewritten title.

COMPOSITIONS AND DOSAGE FORMS FOR GASTRIC DELIVERY OF
~~ANTINEOPLASTIC AGENTS~~IRINOTECAN AND METHODS OF TREATMENT THAT
USE ~~THE~~MIT TO INHIBIT CANCER CELL PROLIFERATION

Please replace the paragraph beginning on page 3, line 3 with the following rewritten paragraph.

Oral delivery, with the convenience of self administration and home dosing, would ease the burden on the patient and care giver imposed by a more frequent dosing schedule. However, the oral bioavailability of irinotecan is reported to be only about 20% of its i.v. bioavailability. Kuhn, J. G., *Ibid* "Pharmacology of Irinotecan" *Oncology* (1998), **12** supp. 6, 39-42; Drentler, R. L., *Ibid*. Serious problems of absorption and pre-systemic metabolism of irinotecan need to be overcome before oral delivery becomes available as a treatment option.